Compare Nucor Corporation (NUE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Nucor Corporation trades at $250.33 (market cap $55.84B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Nucor Corporation is far larger — about 5.5× State Street SPDR S&P Biotech ETF's market cap, and Nucor Corporation pays a 0.91% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nucor Corporation for 78 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| NUE | XBI | |
|---|---|---|
Market Cap | $55.84B | $10.11B |
Volume | 848,835 | 12,903,266 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $274.74 | $169.55 |
52-Week Low | $131.78 | $104.99 |
Typical Hold Time | 78 Days | 38 Days |
Enterprise Value | $60.25B | — |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $246.14, down 0.12% on the day, with a bearish technical signal from moving averages despite recent earnings beats. The company reported strong Q2 2026 EPS of $4.84, beating expectations, and issued Q3 2026 guidance anticipating higher earnings. Revenue is projected to grow to $36.1B in 2026, with net income margin improving to 7.98%. Analyst consensus is a 'Moderate Buy' with a $266.88 price target, suggesting potential upside from current levels.
The outlook for NUE is cautiously optimistic, supported by earnings momentum and steel price strength, but tempered by competitive pressures and cyclical industry risks. Investment opportunity lies in execution of growth initiatives and dividend consistency, while key risks include economic sensitivity and new capacity additions in the steel sector impacting pricing power.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
